Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180955 | 0.81 | DRD2 (0.40) | CYP17A1DRD2 | |
| SCHEMBL2296275 | 0.76 | ALDH1A1 (0.40) | ALDH1A1ADRA2CCYP3A4CYP17A1GAA | |
| SCHEMBL5570972 | 0.74 | CYP17A1 (0.45) | ALDH1A1ADRA2CCYP17A1KDM1AMAOA | |
| SCHEMBL1180713 | 0.67 | CYP17A1 (0.44) | ALDH1A1CYP3A4CYP17A1CHRNB1CHRNB2 | |
| SCHEMBL9200895 | 0.66 | SIGMAR1 (0.39) | — | |
| SCHEMBL13888944 | 0.62 | MAOB (0.50) | ALDH1A1CYP3A4GAAKDM1AHSD11B1 | |
| SCHEMBL12188964 | 0.62 | MAOB (0.50) | ALDH1A1CYP3A4GAAKDM1AHSD11B1 | |
| SCHEMBL7771681 | 0.59 | CYP19A1 (0.62) | — | |
| SCHEMBL5211872 | 0.58 | DRD2 (0.50) | ALDH1A1GAAKDM1AMAOAMAOB | |
| SCHEMBL4470636 | 0.57 | SMN1; SMN2 (0.50) | ALDH1A1KDM1AMAOAMAOBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8008334-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | HEROLD PETER | 2011-02-03 | — | — | US | disclosed |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| EP-1957489-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007065942-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | CYP11B1, CYP11B2, REN | ALDH1A1 249/4885ADRA2C 176/4885CYP3A4 93/4885 |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | REN, CYP11B1, CYP11B2 | ALDH1A1 617/4885ADRA2C 98/4885CYP3A4 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.